Colon Cancer
Show Only Open Trials
1.
A Phase 1a/b Non-Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile Compound 31510 (Ubidecarenone, USP) Nanosuspension for Injection Administered Intravenously to Patients with Solid Tumors
- Study Status: Open to Enrollment
- Sponsor: Berg Pharma
- Disease Status and/or Stage: Advanced Solid Tumors
2.
Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Metastatic Epithelial Cancer
3.
CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Resected Stage III Colon Cancer
- Protocol ID: CALGB 80702
4.
REO 022: A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) in Patients with Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer
- Study Status: Closed to Enrollment
- Sponsor: Oncolytics Biotech, Inc.
- Disease Status and/or Stage: Colon Cancer
5.
A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer
- Study Status: Closed to Enrollment
- Sponsor: Mayo Clinic, National Cancer Institute
- Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
6.
A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Solid Tumor
